Literature DB >> 20858706

Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.

W E Fantegrossi1, J Simoneau, M S Cohen, S M Zimmerman, C M Henson, K C Rice, J H Woods.   

Abstract

Drug-elicited head-twitch behavior is a useful model for studying hallucinogen activity at 5-HT(2A) receptors in the mouse. Chemically diverse compounds active in this assay yield biphasic dose-effect curves, but there is no compelling explanation for the "descending" portion of these functions. A set of experiments was designed to test the hypothesis that the induction of head-twitch behavior is mediated by agonist actions at 5-HT(2A) receptors, whereas the inhibition of head-twitch behavior observed at higher doses results from competing agonist activity at 5-HT(2C) receptors. The effects of the phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) on head-twitch behavior were studied over a range of doses in the mouse, generating a characteristic biphasic dose-response curve. Pretreatment with the selective 5-HT(2A) antagonist (+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol (M100907) shifted only the ascending limb of the DOI dose-effect function, whereas pretreatment with the nonselective 5-HT(2A/2C) antagonist 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione (ketanserin) produced a parallel shift to the right in the DOI dose-response curve. Administration of the 5-HT(2C) agonist S-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine (Ro 60-0175) noncompetitively inhibited DOI-elicited head-twitch behavior across the entire dose-effect function. Finally, pretreatment with the selective 5-HT(2C) antagonists 6-chloro-5-methyl-1-[(2-[2-methylpyrid-3-yloxy]pyrid-5yl)carbamoyl]indoline (SB242084) or 8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulfonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4,5]decane-2,4-dione hydrochloride (RS 102221) did not alter DOI-elicited head-twitch behavior on the ascending limb of the dose-response curve but shifted the descending limb of the DOI dose-response function to the right. The results of these experiments provide strong evidence that DOI-elicited head-twitch behavior is a 5-HT(2A) agonist-mediated effect, with subsequent inhibition of head-twitch behavior being driven by competing 5-HT(2C) agonist activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858706      PMCID: PMC2993545          DOI: 10.1124/jpet.110.172247

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice.

Authors:  S J Corne; R W Pickering
Journal:  Psychopharmacologia       Date:  1967

2.  Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers.

Authors:  R Ortmann; S Bischoff; E Radeke; O Buech; A Delini-Stula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

3.  Two distinct central serotonin receptors with different physiological functions.

Authors:  S J Peroutka; R M Lebovitz; S H Snyder
Journal:  Science       Date:  1981-05-15       Impact factor: 47.728

4.  Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.

Authors:  S P Vickers; N Easton; C S Malcolm; N H Allen; R H Porter; M J Bickerdike; G A Kennett
Journal:  Pharmacol Biochem Behav       Date:  2001 Jul-Aug       Impact factor: 3.533

5.  Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice.

Authors:  H H Berendsen; C L Broekkamp
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

6.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

7.  Withdrawal from chronic treatment with (+/-)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice.

Authors:  N A Darmani; B R Martin; R A Glennon
Journal:  Eur J Pharmacol       Date:  1990-09-04       Impact factor: 4.432

8.  Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone.

Authors:  A R Green; K O'Shaughnessy; M Hammond; M Schächter; D G Grahame-Smith
Journal:  Neuropharmacology       Date:  1983-05       Impact factor: 5.250

9.  The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist.

Authors:  F C Colpaert; P A Janssen
Journal:  Neuropharmacology       Date:  1983-08       Impact factor: 5.250

10.  Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice.

Authors:  William E Fantegrossi; Christina Lynn Kiessel; P Tarn Leach; C Van Martin; Rachel Lynn Karabenick; X Chen; Y Ohizumi; Thomas Ullrich; Kenner C Rice; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2004-01-22       Impact factor: 4.530

View more
  44 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.

Authors:  Mario de la Fuente Revenga; Urjita H Shah; Nima Nassehi; Alaina M Jaster; Prithvi Hemanth; Salvador Sierra; Malgorzata Dukat; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2021-01-05       Impact factor: 4.418

3.  Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.

Authors:  Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

4.  An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice.

Authors:  Meredith A Fox; Micaella G Panessiti; F Scott Hall; George R Uhl; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

5.  Characterization of the discriminative stimulus effects of lorcaserin in rats.

Authors:  Katherine M Serafine; Kenner C Rice; Charles P France
Journal:  J Exp Anal Behav       Date:  2016-09-18       Impact factor: 2.468

6.  Directly Observable Behavioral Effects of Lorcaserin in Rats.

Authors:  Katherine M Serafine; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2015-09-17       Impact factor: 4.030

Review 7.  Animal models of serotonergic psychedelics.

Authors:  James B Hanks; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

8.  Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.

Authors:  Adam L Halberstadt; Susan B Powell; Mark A Geyer
Journal:  Neuropharmacology       Date:  2013-01-29       Impact factor: 5.250

9.  Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.

Authors:  Clinton E Canal; Raymond G Booth; Drake Morgan
Journal:  Neuropharmacology       Date:  2013-01-23       Impact factor: 5.250

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.